GlassScriptPhysician profile
Andrew Donovan
NPI 1407353139
$770.28
in general payments reported to CMS, 2019-2025
16 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.24 · 2023: $56.98 · 2024: $243 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $216.71 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Novocure INC. | $119.70 | 2025 | Optune Gio |
| Merck Sharp & Dohme LLC | $78.85 | 2024-2025 | Keytruda, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $40.26 | 2025 | Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $38.86 | 2025 | |
| Amarin Pharma, INC. | $37.98 | 2023 | |
| Indivior INC. | $25.12 | 2024 | Sublocade |
| Taiho Oncology, INC. | $25.05 | 2025 | |
| Servier Pharmaceuticals LLC | $21.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.30 | 2024 | Fruzaqla |
| Pfizer INC. | $20.55 | 2024 | |
| Blue Earth Diagnostics | $20.48 | 2025 | Posluma |
| Amgen INC. | $19.00 | 2023 | Prolia, Evenity |
| Si-Bone, INC. | $18.24 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.88 | 2025 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.